{
    "clinical_study": {
        "@rank": "8356", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab biosimilar (BEVZ92).", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab 25 mg/mL (strength: 100 mg/4 mL)."
            }, 
            {
                "arm_group_label": "Avastin\u00ae (bevacizumab, reference product)", 
                "arm_group_type": "Active Comparator", 
                "description": "Bevacizumab 25mg/ml (strenght: 100mg/4ml)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a  multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab\n      biosimilar) and Avastin\u00ae with 2 parallel arms to compare the PK profile of BEVZ92 and\n      Avastin\u00ae in combination with FOLFOX (any) or FOLFIRI chemotherapy.\n\n      FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital\n      standard of care."
        }, 
        "brief_title": "Study to Compare and Evaluate the Pharmacokinetic (PK) and Safety Profile of Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN\u00ae) as First-line Treatment in Patients With Metastatic ColoRectal Cancer (mCRC)", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer.", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Planned enrolment duration: 12 months. Pre-treatment period (included in enrolment period):\n      1 month. Treatment period: Patients will continue treatment until disease progression or\n      unacceptable toxicity, or withdrawal of consent."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient must not have had prior chemotherapy for advanced or metastatic disease.\n             Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.\n\n          2. Patient with mCRC for whom bio-chemotherapy is indicated.\n\n          3. Patients must have at least one measurable non-irradiated site of disease according\n             to RECIST (version 1.1) criteria. If the patient has had previous irradiation of the\n             marker lesion(s), there must be evidence of progression since the radiation.\n\n          4. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of\n             all prior systemic anticancer therapy\n\n          5. ECOG performance status \u2264 2.\n\n          6. Adequate bone marrow function\n\n          7. Adequate liver function defined within specific parameters\n\n          8. Adequate renal function defined within specific parameters\n\n          9. Adequate coagulation parameters defined within specific parameters\n\n         10. Negative pregnancy test for females of a childbearing potential.\n\n         11. Use of an effective form of contraception during the study (for subjects of\n             childbearing potential and their partners).\n\n         12. Life expectation \u2265 3 months\n\n        Exclusion Criteria:\n\n          1. Prior treatment for advanced or metastatic colorectal cancer.\n\n          2. Prior treatment with an anti-angiogenesis agent, in either the neoadjuvant or\n             adjuvant setting.\n\n          3. Concurrent use of investigational anti-neoplastic agents (including up to 4 weeks\n             prior to enrolment).\n\n          4. History of any other malignancy unless the malignancy is in complete remission and\n             the patient has been off all therapy for that malignancy for at least 5 years.\n\n          5. Chronic treatment with systemic steroids or other immunosuppressive agents; topical\n             or inhaled corticosteroids are allowed.\n\n          6. Scheduled immunization with attenuated live vaccines during study period or within 1\n             week prior to study entry.\n\n          7. Uncontrolled brain or lepto-meningeal metastases, including patients who continue to\n             require glucocorticoids for brain or lepto-meningeal metastases.\n\n          8. Patients with active bleeding or history of bleeding diathesis on oral anti-vitamin K\n             medication (except low dose coumadin) within the past 6 month prior to randomization\n             or coagulopathy.\n\n          9. Patients with history of cerebral vascular accident, transient ischemic attack, or\n             subarachnoid haemorrhage within the past 6 month prior to randomization.\n\n         10. Patients who have any severe and/or uncontrolled medical conditions or other\n             conditions that could affect their participation in the study\n\n         11. Patients with serious non-healing wound, ulcer, bone fracture, or with a major\n             surgical procedure, or significant traumatic injury within  4 weeks prior to\n             randomization\n\n         12. Patients with clinical symptoms or signs of gastrointestinal obstruction that require\n             parenteral hydration and/or nutrition.\n\n         13. Patients with history of abdominal fistula, gastrointestinal perforation, or\n             intra-abdominal abscess within the past 6 months prior to randomization.\n\n         14. Patients with history of hypersensitivity to any of the study drugs or ingredients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069704", 
            "org_study_id": "BEVZ92-A-01-13", 
            "secondary_id": "BEVZ92-A-01-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bevacizumab biosimilar (BEVZ92).", 
                "description": "Bevacizumab biosimilar (BEVZ92), Active ingredient Bevacizumab 25 mg/mL (strength = 100mg/mL).  30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy (Folfox any or Folfiri).\nFOLFIRI = Folinic Acid + Fluorouracil + Irinitecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).\n*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.\nThe FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.", 
                "intervention_name": "Experimental: Bevacizumab biosimilar (BEVZ92).", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Avastin\u00ae (bevacizumab, reference product)", 
                "description": "Avastin\u00ae (bevacizumab, reference product). Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).\n*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.\nThe FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.", 
                "intervention_name": "Active Comparator: Avastin\u00ae (bevacizumab, reference product)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FOLFOX = Fol\u00ednic acid + Fluorouracil + Irinitecan", 
                    "FOLFIRI = Fol\u00ednic acid + Fluorouracil + Oxaliplatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Bevacizumab", 
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "colorectal cancer", 
            "metastatic", 
            "first-line treatment", 
            "comparability"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barretos", 
                        "country": "Brazil"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sau Paulo", 
                        "country": "Brazil"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chennai", 
                        "country": "India"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karamsand", 
                        "country": "India"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashik", 
                        "country": "India"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thiruvananthapuram", 
                        "country": "India"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arequipa", 
                        "country": "Peru"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leningrad Region", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Petersburg", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dnipropetrovsk", 
                        "country": "Ukraine"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lviv", 
                        "country": "Ukraine"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Argentina", 
                "Brazil", 
                "India", 
                "Peru", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic (PK) and Safety Profile of Bevacizumab Biosimilar (BEVZ92) in Combination With FOLFOX or FOLFIRI Vs Bevacizumab (AVASTIN\u00ae) in Combination With FOLFOX or FOLFIRI as First-line Treatment in Patients With Metastatic ColoRectal Cancer (mCRC)", 
        "overall_contact": {
            "email": "pilar.sanjuan@chemogroup.net", 
            "last_name": "Pilar Sanjuan Sanz, MSc", 
            "phone": "003491 3021560", 
            "phone_ext": "9575"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Ukraine: State Pharmacological Center - Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To compare the PK profile of BEVZ92 and Avastin\u00ae, both administered in combination with FOLFOX (any) or FOLFIRI", 
            "safety_issue": "No", 
            "time_frame": "Week 1, week 3, week 9, week 13 and week 15. Up to 15 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "SECONDARY OBJECTIVES\nComparation of safety profile between both arms\nComparison of immunogenicity of BEVZ92 and Avastin\u00ae in combination with FOLFOX (any) or FOLFIRI.\nEfficacy: Comparison of Objective Response Rate (ORR) and progression-free survival (PFS) between the randomized treatment arms", 
            "measure": "Safety, immunogenicity and efficacy profile", 
            "safety_issue": "Yes", 
            "time_frame": "Every four weeks. Up to 48 weeks"
        }, 
        "source": "mAbxience S.A", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Laboratorio Elea S.A.C.I.F. y A.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "LIBBS", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "mAbxience S.A", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}